Forte Biosciences (FBRX) EBIT Margin (2016 - 2020)
Historic EBIT Margin for Forte Biosciences (FBRX) over the last 5 years, with Q1 2020 value amounting to 1150.4%.
- Forte Biosciences' EBIT Margin rose 1886059500.0% to 1150.4% in Q1 2020 from the same period last year, while for Mar 2020 it was 7316.46%, marking a year-over-year increase of 75930100.0%. This contributed to the annual value of 170863.89% for FY2019, which is 1706096600.0% down from last year.
- Forte Biosciences' EBIT Margin amounted to 1150.4% in Q1 2020, which was up 1886059500.0% from 118911.11% recorded in Q4 2019.
- In the past 5 years, Forte Biosciences' EBIT Margin ranged from a high of 1706.2% in Q3 2016 and a low of 212311.11% during Q4 2018
- Its 5-year average for EBIT Margin is 87685.79%, with a median of 97370.0% in 2017.
- Per our database at Business Quant, Forte Biosciences' EBIT Margin plummeted by -1902634800bps in 2019 and then soared by 1886059500bps in 2020.
- Quarter analysis of 5 years shows Forte Biosciences' EBIT Margin stood at 1527.39% in 2016, then crashed by -7097bps to 106870.0% in 2017, then plummeted by -99bps to 212311.11% in 2018, then surged by 44bps to 118911.11% in 2019, then skyrocketed by 101bps to 1150.4% in 2020.
- Its EBIT Margin was 1150.4% in Q1 2020, compared to 118911.11% in Q4 2019 and 190255.56% in Q3 2019.